Myriad settles BRCA litigation following Federal Circuit ruling
Myriad Genetics has settled litigation with three of the laboratories it accused of infringing patents on two genes associated with breast and ovarian cancer, following a Federal Circuit ruling last month confirming some of its claims were patent ineligible
The molecular diagnostic company has reached settlements with LabCorp, Invitae, and Pathway Genomics. A statement announcing a settlement was also issued by Ambry, but was quickly retracted. The statement was inadvertently sent out, according to PBS. Myriad is reportedly discussing...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.